Acrivastine
Semprex (acrivastine) is a small molecule pharmaceutical. Acrivastine was first approved as Semprex-d on 1994-03-25. It is used to treat allergic rhinitis perennial and urticaria in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acrivastine
+
Pseudoephedrine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SEMPREX-D | Auxilium Pharmaceuticals | N-019806 DISCN | 1994-03-25 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
semprex-d | 2008-05-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ACRIVASTINE |
INN | acrivastine |
Description | Acrivastine is a member of the class of pyridines that is (pyridin-2-yl)acrylic acid substituted at position 6 by a [(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl group. It is a non-sedating antihistamine used for treatment of hayfever, urticaria, and rhinitis. It has a role as a H1-receptor antagonist. It is an alpha,beta-unsaturated monocarboxylic acid, a member of pyridines, a N-alkylpyrrolidine and an olefinic compound. |
Classification | Small molecule |
Drug class | antihistaminics (histamine-H1 receptor antagonists) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1 |
Identifiers
PDB | — |
CAS-ID | 87848-99-5 |
RxCUI | 19959 |
ChEMBL ID | CHEMBL1224 |
ChEBI ID | 83168 |
PubChem CID | 5284514 |
DrugBank | DB09488 |
UNII ID | A20F9XAI7W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 172 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
453 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more